The consequences of not having eosinophils

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 7, 2013, Pages 829-835

  Gleich, G J ^a   Klion, A D ^b   Lee, J J ^c   Weller, P F ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anti interleukin 5; deficiency; eosinophil; thymoma

Indexed keywords

BENRALIZUMAB; INTERLEUKIN 5; MEPOLIZUMAB; MONOCLONAL ANTIBODY; PLACEBO; RESLIZUMAB;

ALLERGIC DISEASE; ASTHMA; BASOPHIL; BONE MARROW CELL; COLONY FORMATION; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; DYSGAMMAGLOBULINEMIA; EOSINOPHIL; GLUCOSE METABOLISM; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVIEW; THYMOMA;

ANTI-INTERLEUKIN 5; DEFICIENCY; EOSINOPHIL; THYMOMA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DISEASE MODELS, ANIMAL; EOSINOPHILS; FEMALE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; INTERLEUKIN-5; LEUKOCYTE COUNT; MALE; MICE; PROGNOSIS; RISK ASSESSMENT; THYMOMA; THYMUS NEOPLASMS;

EID: 84880290861     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12169     Document Type: Review

References (54)

1. Ehrlich P, Lazarus A, Myers W, Woodhead G,. Histology of the Blood: Normal and Pathological. Cambridge: Printed by J. and C. F. Clay, at the University Press, 1900.
2. Gleich GJ, Adolphson CR,. The eosinophilic leukocyte: structure and function. Adv Immunol 1986; 39: 177-253.
3. Petreccia DC, Nauseef WM, Clark RA,. Respiratory burst of normal human eosinophils. J Leukoc Biol 1987; 41: 283-288.
4. Good RA, Varco RL,. A clinical and experimental study of agammaglobulinemia. J Lancet 1955; 75: 245-271.
5. Ramos AJ,. Presentation of case. J Am Med Assoc 1956; 160: 1317-1319.
6. Waldmann TA, Strober W, Blaese RM, Strauss AJL,. Thymoma, Hypogammaglobulinemia, and Absence of Eosinophils. J Clin Investig 1967; 46: 1127-1128.
7. Jeunet FS, Good RA,. Thymoma, Immunogic Deficiencies and Hematological Abnormalities. Birth Defects Original Series 1968; 4: 192-206.
8. Beeson PB, Bass DA,. The Eosinophil. Philadelphia: Saunders, 1977.
9. Juhlin L, Michaelsson G,. A new syndrome characterised by absence of eosinophils and basophils. Lancet 1977; 1: 1233-1235.
10. Juhlin L, Venge P,. Total absence of eosinophils in a patient with chronic urticaria and vitiligo. Eur J Haematol 1988; 40: 368-370.
11. Mitchell EB, Platts-Mills TA, Pereira RS, Malkovska V, Webster AD,. Acquired basophil and eosinophil deficiency in a patient with hypogammaglobulinaemia associated with thymoma. Clin Lab Haematol 1983; 5: 253-257.
12. Forssman O, Korsgren M,. Aneosinophilia in a patient with bronchial asthma. Acta Med Scand 1962; 172: 1-4.
13. Knapik Z, Tarnawski S,. [Primary aneosinophilia]. Pol Tyg Lek (Wars) 1957; 12: 1579-1581.
14. Franklin W, Goetzl EJ,. Total absence of eosinophils in a patient with an allergic disorder. Ann Intern Med 1981; 94: 352-353.
15. Nakahata T, Spicer SS, Leary AG, Ogawa M, Franklin W, Goetzl EJ,. Circulating eosinophil colony-forming cells in pure eosinophil aplasia. Ann Intern Med 1984; 101: 321-324.
16. Krantz SB, Kao V,. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA 1967; 58: 493-500.
17. Telerman A, Amson RB, Delforge A, Collard E, Stryckmans PA,. A case of chronic aneosinocytosis. Am J Hematol 1982; 12: 187-197.
18. Krause JR, Boggs DR,. Search for eosinopenia in hospitalized patients with normal blood leukocyte concentration. Am J Hematol 1987; 24: 55-63.
19. Gleich GJ, Loegering DA, Olson GM,. Reactivity of rabbit antiserum to guinea pig eosinophils. J Immunol 1975; 115: 950-954.
20. Gleich GJ, Olson GM, Loegering DA,. The effect of ablation of eosinophils on immediate-type hypersensitivity reactions. Immunology 1979; 38: 343-353.
21. Gleich GJ, Olson GM, Herlich H,. The effect of antiserum to eosinophils and susceptibility and acquired immunity of the guinea-pig to trichostrongylus colubriformis. Immunology 1979; 37: 873-880.
22. Kung TT, Stelts DM, Zurcher JA, Adams GK III, Egan RW, Kreutner W, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995; 13: 360-365.
23. Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK III, Kreutner W, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995; 152: 467-472.
24. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002; 195: 1387-1395.
25. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776-1779.
26. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004; 305: 1773-1776.
27. Swartz JM, Dyer KD, Cheever AW, Ramalingam T, Pesnicak L, Domachowske JB, et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 2006; 108: 2420-2427.
28. O'Connell AE, Hess JA, Santiago GA, Nolan TJ, Lok JB, Lee JJ, et al. Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to Strongyloides stercoralis in mice. Infect Immun 2011; 79: 2770-2778.
29. Fabre V, Beiting DP, Bliss SK, Gebreselassie NG, Gagliardo LF, Lee NA, et al. Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol 2009; 182: 1577-1583.
30. Jacobsen EA, Ochkur SI, Pero RS, Taranova AG, Protheroe CA, Colbert DC, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med 2008; 205: 699-710.
31. Jacobsen EA, Zellner KR, Colbert D, Lee NA, Lee JJ,. Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation. J Immunol 2011; 187: 6059-6068.
32. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011; 12: 151-159.
33. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011; 332: 243-247.
34. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007; 178: 4222-4229.
35. Wong DT, Bowen SM, Elovic A, Gallagher GT, Weller PF,. Eosinophil ablation and tumor development. Oral Oncol 1999; 35: 496-501.
36. Loughnan MS, Takatsu K, Harada N, Nossal GJ,. T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. Proc Natl Acad Sci USA 1987; 84: 5399-5403.
37. Campbell HD, Tucker WQ, Hort Y, Martinson ME, Mayo G, Clutterbuck EJ, et al. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci USA 1987; 84: 6629-6633.
38. Yokota T, Coffman RL, Hagiwara H, Rennick DM, Takebe Y, Yokota K, et al. Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. Proc Natl Acad Sci USA 1987; 84: 7388-7392.
39. Hamelmann E, Gelfand EW,. IL-5-induced airway eosinophilia-the key to asthma? Immunol Rev 2001; 179: 182-191.
40. Simon D, Braathen LR, Simon HU,. Eosinophils and atopic dermatitis. Allergy 2004; 59: 561-570.
41. Gross WL,. Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol 2002; 14: 11-14.
42. Gleich GJ, Leiferman KM,. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol 2009; 145: 271-285.
43. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA,. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219-224.
44. Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001; 108: 250-257.
45. Egan RW, Athwahl D, Chou CC, Chapman RW, Emtage S, Jenh CH, et al. Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz 1997; 92 (Suppl 2): 69-73.
46. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228.
47. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
48. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
49. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
50. Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 2013; 131: 461-467.
51. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
52. Ghazi A, Trikha A, Calhoun WJ,. Benralizumab-a humanized mAb to IL-5R alpha with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012; 12: 113-118.
53. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125: 1237-1244.
54. Bogomolski-Yahalom V, Matzner Y,. Disorders of neutrophil function. Blood Rev 1995; 9: 183-190.